TY - JOUR
T1 - The pharmacodynamic-toxicodynamic relationship of auc and cmax in vancomycin-induced kidney injury in an animal model
AU - Avedissian, Sean N.
AU - Pais, Gwendolyn
AU - Liu, Jiajun
AU - Nicholas O'Donnell, J.
AU - Lodise, Thomas P.
AU - Neely, Michael
AU - Prozialeck, Walter C.
AU - Lamar, Peter C.
AU - Becher, Leighton
AU - Scheetz, Marc H.
N1 - Publisher Copyright:
© 2021 American Society for Microbiology. All rights reserved.
PY - 2021/3
Y1 - 2021/3
N2 - Vancomycin induces exposure-related acute kidney injury. However, the pharmacokinetic-toxicodynamic (PK-TD) relationship remains unclear. Sprague-Dawley rats received intravenous (i.v.) vancomycin doses of 300mg/kg/day and 400mg/kg/day, divided into once-, twice-, three-times-, or four-times-daily doses (i.e., QD, BID, TID, or QID) over 24 h. Up to 8 samples plus a terminal sample were drawn during the 24-h dosing period. Twenty-four-hour urine was collected and assayed for kidney injury molecule- 1 (KIM-1). Vancomycin was quantified via liquid chromatography-tandem mass spectrometry (LC-MS/MS). Following terminal sampling, nephrectomy and histopathologic analyses were conducted. PK analyses were conducted using Pmetrics. PK exposures (i.e., area under the concentration-time curve from 0 to 24 h [AUC0-24] and maximum concentration from 0 to 24 h [Cmax0-24]) were calculated for each rat, and PK-TD relationships were discerned. A total of 53-rats generated PK-TD data. A 2-compartment model fit the data well (Bayesian observed versus predicted concentrations; R2 = 0.96). KIM-1 values were greater in QD and BID groups (P for QD versus TID, ,0.002; P for QD versus QID, ,0.004; P for BID versus TID, ,0.002; and P for BID versus QID, ,0.004). Exposure- response relationships were observed between KIM-1 versus Cmax0-24 and AUC0-24 (R2 = 0.7 and 0.68). Corrected Akaike's information criterion showed Cmax0-24 as the most predictive PK-TD driver for vancomycin-induced kidney injury (VIKI) (25.28 versus 21.95). While PK-TD indices are often intercorrelated, maximal concentrations and fewer doses (for the same total daily amount) resulted in increased VIKI in our rat model.
AB - Vancomycin induces exposure-related acute kidney injury. However, the pharmacokinetic-toxicodynamic (PK-TD) relationship remains unclear. Sprague-Dawley rats received intravenous (i.v.) vancomycin doses of 300mg/kg/day and 400mg/kg/day, divided into once-, twice-, three-times-, or four-times-daily doses (i.e., QD, BID, TID, or QID) over 24 h. Up to 8 samples plus a terminal sample were drawn during the 24-h dosing period. Twenty-four-hour urine was collected and assayed for kidney injury molecule- 1 (KIM-1). Vancomycin was quantified via liquid chromatography-tandem mass spectrometry (LC-MS/MS). Following terminal sampling, nephrectomy and histopathologic analyses were conducted. PK analyses were conducted using Pmetrics. PK exposures (i.e., area under the concentration-time curve from 0 to 24 h [AUC0-24] and maximum concentration from 0 to 24 h [Cmax0-24]) were calculated for each rat, and PK-TD relationships were discerned. A total of 53-rats generated PK-TD data. A 2-compartment model fit the data well (Bayesian observed versus predicted concentrations; R2 = 0.96). KIM-1 values were greater in QD and BID groups (P for QD versus TID, ,0.002; P for QD versus QID, ,0.004; P for BID versus TID, ,0.002; and P for BID versus QID, ,0.004). Exposure- response relationships were observed between KIM-1 versus Cmax0-24 and AUC0-24 (R2 = 0.7 and 0.68). Corrected Akaike's information criterion showed Cmax0-24 as the most predictive PK-TD driver for vancomycin-induced kidney injury (VIKI) (25.28 versus 21.95). While PK-TD indices are often intercorrelated, maximal concentrations and fewer doses (for the same total daily amount) resulted in increased VIKI in our rat model.
KW - Pharmacodynamics
KW - Pharmacokinetics
KW - Pharmacology
KW - Rat
KW - Toxicodynamics
KW - Vancomycin
UR - http://www.scopus.com/inward/record.url?scp=85101767832&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101767832&partnerID=8YFLogxK
U2 - 10.1128/AAC.01945-20
DO - 10.1128/AAC.01945-20
M3 - Article
C2 - 33318004
AN - SCOPUS:85101767832
SN - 0066-4804
VL - 65
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 3
M1 - e01945-20
ER -